Long acting injectable antipsychotic medications: Ensuring care continuity during the COVID-19 pandemic restrictions
- PMID: 32389613
- PMCID: PMC7203049
- DOI: 10.1016/j.schres.2020.05.001
Long acting injectable antipsychotic medications: Ensuring care continuity during the COVID-19 pandemic restrictions
Conflict of interest statement
None of the authors has any conflicts of interest with reference to this article.
Figures
Comment on
-
Long-acting injectable antipsychotics treatment during COVID-19 pandemic - A new challenge.Schizophr Res. 2020 Jun;220:265-266. doi: 10.1016/j.schres.2020.04.030. Epub 2020 Apr 27. Schizophr Res. 2020. PMID: 32349886 Free PMC article. No abstract available.
References
-
- Greene M., Yan T., Chang E. Medication adherence and discontinuation of long-acting injectable versus oral antipsychotics in patients with schizophrenia or bipolar disorder. J. Med. Econ. 2018;21(2):127–134. Feb. - PubMed
-
- Kishimoto T., Nitta M., Borenstein M. Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies. J Clin Psychiatry. 2013;74(10):957–965. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources